Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness

Shan Wan, Anne‐Sophie Meyer, Sofia Maria Elisabeth Weiler, Christian Rupp, Marcell Tóth, Carsten Sticht, Stephan Singer, Stefan Thomann, Stephanie Roessler, Marina Schorpp‐Kistner, Jennifer Schmitt, Norbert Gretz, Peter Angel, Darjus Felix Tschaharganeh, Jens Marquardt, Peter Schirmacher, Federico Pinna, Kai Breuhahn – 20 November 2017 – The loss of epithelial cell polarity plays an important role in the development and progression of liver cancer. However, the specific molecular mechanisms supporting tumor initiation and progression are poorly understood.

Development and validation of a primary sclerosing cholangitis–specific patient‐reported outcomes instrument: The PSC PRO

Zobair M. Younossi, Arian Afendy, Maria Stepanova, Andrei Racila, Fatema Nader, Rachel Gomel, Ricky Safer, William R. Lenderking, Anne Skalicky, Leah Kleinman, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Cynthia Levy, Christopher L. Bowlus, Kris Kowdley, Andrew J. Muir – 20 November 2017 – Primary sclerosing cholangitis (PSC) is a chronic liver disease associated with inflammation and biliary fibrosis that leads to cholangitis, cirrhosis, and impaired quality of life. Our objective was to develop and validate a PSC‐specific patient‐reported outcome (PRO) instrument.

New insights into diagnosis and therapeutic options for proliferative hepatoblastoma

Katarzyna B. Hooks, Jérôme Audoux, Helena Fazli, Sarah Lesjean, Tony Ernault, Nathalie Dugot‐Senant, Thierry Leste‐Lasserre, Martin Hagedorn, Benoit Rousseau, Coralie Danet, Sophie Branchereau, Laurence Brugières, Sophie Taque, Catherine Guettier, Monique Fabre, Anne Rullier, Marie‐Annick Buendia, Thérèse Commes, Christophe F. Grosset, Anne‐Aurélie Raymond – 20 November 2017 – Surgery and cisplatin‐based treatment of hepatoblastoma (HB) currently guarantee the survival of 70%‐80% of patients.

Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice

Esther Nuñez‐Durán, Mariam Aghajan, Manoj Amrutkar, Silva Sütt, Emmelie Cansby, Sheri L. Booten, Andrew Watt, Marcus Ståhlman, Norbert Stefan, Hans‐Ulrich Häring, Harald Staiger, Jan Borén, Hanns‐Ulrich Marschall, Margit Mahlapuu – 20 November 2017 – Nonalcoholic fatty liver disease (NAFLD) contributes to the pathogenesis of type 2 diabetes and cardiovascular disease, and patients with nonalcoholic steatohepatitis (NASH) are also at risk of developing cirrhosis, liver failure, and hepatocellular carcinoma.

Subscribe to